

June 5, 2026

To, National Stock Exchange of India Limited, “Exchange Plaza”, 5th Floor, Plot No. C/1, G Block, Bandra- Kurla Complex, Bandra (East), Mumbai – 400 051	To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001
Scrip Name: GLENMARK	Scrip Code: 532296
ISIN: INE935A01035	ISIN: INE935A01035
Our Reference No. 20/26-27	Our Reference No. 20/26-27

Dear Sir/ Madam,

**Sub: Transcript of the Earnings Call**

Further to our letter dated May 23, 2026 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (LODR), Regulations 2015, the transcript of the Earnings call held on Monday, June 01, 2026 for the fourth quarter and year ended March 31, 2026 has been uploaded on the Company's website at [https://glenmark.b-cdn.net//gpl\\_pdfs/Financials/Quarterly/Earnings%20Call%20Transcript%20Q4%20FY26.pdf](https://glenmark.b-cdn.net//gpl_pdfs/Financials/Quarterly/Earnings%20Call%20Transcript%20Q4%20FY26.pdf)

Request you to kindly take the same on record.

Thanking you.

Yours faithfully,

**For Glenmark Pharmaceuticals Limited**

**Rashmi Khandelwal**  
**Company Secretary & Compliance Officer**  
**ACS - 28839**

**Glenmark Pharmaceuticals Limited**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)